Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 19/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008327 | 0.87 | CCNT1 (0.45) | CCNT1CDK9BTK | |
| SCHEMBL14500649 | 0.84 | CCNT1 (0.67) | CCNT1CDK9BTK | |
| SCHEMBL5005001 | 0.82 | CCNT1 (0.58) | CCNT1CDK9BTK | |
| SCHEMBL18979740 | 0.79 | CCNT1 (0.51) | CCNT1CDK9BTK | |
| SCHEMBL14645726 | 0.79 | BTK (0.72) | BTK | |
| SCHEMBL16049023 | 0.79 | BTK (0.63) | CCNT1CDK9BTK | |
| SCHEMBL14646746 | 0.79 | BTK (0.69) | BTK | |
| SCHEMBL5005732 | 0.78 | CCNT1 (0.58) | CCNT1CDK9BTK | |
| SCHEMBL14646842 | 0.77 | BTK (0.68) | BTK | |
| SCHEMBL14645723 | 0.77 | BTK (0.70) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346813-B2 | Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2970299-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9233111-B2 | Pyrrolo pyrimidine derivatives | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233111-B2 | Pyrrolo pyrimidine derivatives | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| EP-2729466-B1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014160028-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275004-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| WO-2013008095-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | BTK, LCK, ZAP70 | CCNT1 1574/4885CDK9 180/4885BTK 1/4885 |
| US-20140275004-A1 | PYRROLOPYRIMINDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | CCNT1 36/4885CDK9 1/4885BTK 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.